Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 11/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxfendazole SCHEMBL44121 | 1.00 | LMNA (0.55) | LMNACYP1A2HIF1AALDH1A1KDR | |
| Oxfendazole SCHEMBL27586080 | 0.99 | LMNA (0.54) | LMNACYP1A2HIF1AALDH1A1KDR | |
| Oxfendazole SCHEMBL28641495 | 0.94 | LMNA (0.50) | LMNACYP1A2HIF1AALDH1A1KDR | |
| Oxfendazole SCHEMBL1498223 | 0.91 | LMNA (0.47) | LMNACYP1A2HIF1AALDH1A1KDR | |
| Oxfendazole SCHEMBL9370016 | 0.91 | LMNA (0.67) | LMNACYP1A2HIF1AALDH1A1KDR | |
| Oxfendazole SCHEMBL9818561 | 0.91 | LMNA (0.64) | LMNACYP1A2HIF1AALDH1A1KDR | |
| Oxfendazole SCHEMBL29351297 | 0.91 | LMNA (0.64) | LMNACYP1A2HIF1AALDH1A1KDR | |
| SCHEMBL11666743 | 0.89 | LMNA (0.46) | LMNACYP1A2HIF1AALDH1A1KDR | |
| SCHEMBL11666872 | 0.89 | LMNA (0.50) | LMNACYP1A2HIF1AALDH1A1KDR | |
| SCHEMBL11663674 | 0.89 | RAB9A (0.53) | LMNACYP1A2HIF1AALDH1A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| CN-118344983-A | Aspergillus coronary-process LNFZ-1 and its fermentation process and application | 郑州大学 | 2024-07-16 | — | — | CN | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3448435-B1 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | ROUSSELOT B V (NL) | 2022-06-01 | — | — | EP | claimed |
| EP-3599855-B1 | DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS | Champion USA LLC (US) | 2022-03-02 | — | — | EP | claimed |
| EP-4687961-A1 | NEMATODE VACCINE | New Zealand Institute For Bioeconomy Science Limited (NZ) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20250114393-A1 | CANCER TREATMENT REGIMEN USING ANTI-PARASITIC COMPOUNDS AND GUT MICROBIOME MODULATING AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-04-10 | — | — | US | disclosed |
| EP-3253757-B1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-12194058-B2 | Cancer treatment regimen using anti-parasitic compounds and gut microbiome modulating agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240398915-A1 | NEMATODE VACCINE | AGRESEARCH LIMITED (NZ) | 2024-12-05 | — | — | US | disclosed |
| EP-4036083-A1 | 5-OXY SUBSTITUTED HETEROCYCLES AS PESTICIDES | Bayer Aktiengesellschaft (DE) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022150356-A1 | CANCER TREATMENT REGIMEN USING ANTI-PARASITIC COMPOUNDS AND GUT MICROBIOME MODULATING AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-4003966-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3765465-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3765466-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3615540-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3974414-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PESTICIDES | Bayer AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022053453-A1 | AZOLE CARBOXAMIDE AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | SI, PIM1, PIM3 | LMNA 766/4885CYP1A2 389/4885HIF1A 3884/4885 |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | SI, PIM1, PIM3 | LMNA 766/4885CYP1A2 389/4885HIF1A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.